Uploaded July 2026 | Updated September 2026, 3 weeks ago

---

United Therapeutics acquired Thymmune Therapeutics for $140 million, highlighting growing confidence in immune rejuvenation as a key pillar of longevity medicine. Thymmune's machine learning-enabled thymic cell therapies aim to restore immune function and treat age-related immune decline, bringing the field another step toward clinical translation.

Full Episode on YouTube, Spotify and Apple Podcast. Link in the comment.

#LongevityTechnologyUnlocked #LongevityPodcast #ImmuneRejuvenation #UnitedTherapeutics #ThymicEngineering #LongevityBiotech